Barclays analyst Luke Sergott raised the firm’s price target on Sotera Health (SHC) to $18 from $17 and keeps an Overweight rating on the shares. The firm says “no news is good news” on litigation as the California case count holds steady at 18.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SHC: